Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by t…
This bill (Pharmacy Benefit Manager Reform Act of 2025) imposes new rules and reporting requirements on pharmacy benefit managers (PBMs), Medicare Part D prescription drug plan sponsors (PDP sponsors), Medicare Advantage organizations, group health plans, and State Medicaid arrangements. Key provisions require any willing pharmacy that meets reasonable contract standards to be allowed into Part D networks, create a biannual public listing and reporting regime for “essential retail pharmacies,” establish an allegation and enforcement process with civil monetary penalties, and make PBMs contractually accountable for delegated violations.
Scope and degree of federal intervention: liberals see needed accountability and access protections; conservatives see federal overreach into private contracting.
Relative to its intended legislative type, this bill is a comprehensive substantive policy package that tightly amends multiple statutory authorities to impose transparency, reporting, auditing, and enforcement obligations on pharmacy benefit managers and related actors, while providing definitions, timelines, and appropriations to enable implementation.
This bill (Pharmacy Benefit Manager Reform Act of 2025) imposes new rules and reporting requirements on pharmacy benefit managers (PBMs), Medicare Part D prescription drug plan sponsors (PDP sponsors), Medicare Advantage organizations, group health plans, and State Medicaid arrangements.
Key provisions require any willing pharmacy that meets reasonable contract standards to be allowed into Part D networks, create a biannual public listing and reporting regime for “essential retail pharmacies,” establish an allegation and enforcement process with civil monetary penalties, and make PBMs contractually accountable for delegated violations.
The bill mandates broad, drug- and transaction-level transparency reporting from PBMs to plans and to federal agencies, requires audits and disgorgement of improper remuneration, funds CMS/OIG/GAO/MedPAC studies and reports, and creates Medicaid-specific reforms including a pharmacy price survey, prohibitions on abusive spread pricing, and a pass-through pricing requirement.
On content alone the bill addresses a salient problem and includes some bipartisan-appealing elements (transparency, pharmacy access). Yet it is large, prescriptive, and intrusive into established payment and contracting arrangements, imposes heavy reporting and enforcement obligations, and creates explicit penalties and federal standards that will mobilize well-resourced stakeholders. The multi-statute, cross-jurisdiction nature and substantial administrative complexity reduce the chance it clears both chambers intact; success would likely require significant narrowing, compromise, or incorporation of parts into broader package legislation.
Relative to its intended legislative type, this bill is a comprehensive substantive policy package that tightly amends multiple statutory authorities to impose transparency, reporting, auditing, and enforcement obligations on pharmacy benefit managers and related actors, while providing definitions, timelines, and appropriations to enable implementation.
Scope and degree of federal intervention: liberals see needed accountability and access protections; conservatives see federal overreach into private contracting.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and degree of federal intervention: liberals see needed accountability and access protections; conservatives see federal overreach into private contracting.
A mainstream liberal would likely view this bill favorably as a strong step toward protecting small and rural pharmacies, increasing transparency in drug pricing, and holding PBMs accountable for potentially anti-competitive or opaque practices.
They would see the “any willing pharmacy” requirement, essential pharmacy protections, pass-through pricing in Medicaid, mandatory reporting of rebates and PBM revenue retention, disgorgement, and civil penalties as important tools to reduce abusive practices and ensure access.
They would nevertheless note that many regulatory details are left to the Secretary, so enforcement strength will matter.
A mainstream centrist would cautiously welcome the bill’s aims—greater transparency, anti-spread measures in Medicaid, protections for underserved pharmacies, and stronger enforcement—but would be concerned about implementation complexity, regulatory burden, and fiscal and market side effects.
They would view many provisions as plausible improvements if the Secretary and agencies implement clear, balanced rules and if the reporting/penalty regimes are calibrated to avoid excessive disruption.
A centrist would want stronger cost estimates and phased implementation timelines and would watch for unintended consequences like higher premiums or reduced formulary flexibility.
A mainstream conservative would likely oppose or be skeptical of the bill because it imposes extensive federal mandates, reporting, and regulatory authority over private contracts and market arrangements.
They would view many requirements (detailed drug- and transaction-level reporting, Secretary-defined standards, civil monetary penalties, pass-through pricing mandates) as federal overreach that disrupts market negotiations, increases compliance costs, and risks raising premiums or reducing efficiency.
They might acknowledge the benefits of transparency and rural pharmacy access but prefer narrower, market-based, or state-led solutions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill addresses a salient problem and includes some bipartisan-appealing elements (transparency, pharmacy access). Yet it is large, prescriptive, and intrusive into established payment and contracting arrangements, imposes heavy reporting and enforcement obligations, and creates explicit penalties and federal standards that will mobilize well-resourced stakeholders. The multi-statute, cross-jurisdiction nature and substantial administrative complexity reduce the chance it clears both chambers intact; success would likely require significant narrowing, compromise, or incorporation of parts into broader package legislation.
The bill has not accumulated any surfaced votes yet.
Scope and degree of federal intervention: liberals see needed accountability and access protections; conservatives see federal overreach in…
On content alone the bill addresses a salient problem and includes some bipartisan-appealing elements (transparency, pharmacy access). Yet…
Relative to its intended legislative type, this bill is a comprehensive substantive policy package that tightly amends multiple statutory authorities to impose transparency, reporting, auditing, and enforcement obligati…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.